Discovery of μ,δ-Opioid Receptor Dual-Biased Agonists That Overcome the Limitation of Prior Biased Agonists
Open Access
- 6 April 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 4 (3) , 1149-1160
Abstract
Morphine is widely used in pain management although the risk of side effects is significant. The use of biased agonists to the G protein of μ-opioid receptors has been suggested as a potential solution, although oliceridine and PZM21 have previously failed to demonstrate benefits in clinical studies. An amplification-induced confusion in the process of comparing G protein and beta-arrestin pathways may account for previously biased agonist misidentification. Here, we have devised a strategy to discover biased agonists with intrinsic efficacy. We computationally simulated 430 000 molecular dockings to the μ-opioid receptor to construct a compound library. Hits were then verified experimentally. Using the verified compounds, we performed simulations to build a second library with a common scaffold and selected compounds that showed a bias to μ- and δ-opioid receptors in a cell-based assay. Three compounds (ID110460001, ID110460002, and ID110460003) with a dual-biased agonistic effect for μ- and δ-opioid receptors were identified. These candidates are full agonists for the μ-opioid receptor and show specific binding modes. On the basis of our findings, we expect our novel compounds to act as more biased agonists compared to existing drugs, including oliceridine.Keywords
All Related Versions
This publication has 36 references indexed in Scilit:
- Development of a Peptide-Derived Orally-Active Kappa-Opioid Receptor Agonist Targeting Peripheral PainThe Open Medicinal Chemistry Journal, 2013
- Efficacy and ligand bias at the μ‐opioid receptorBritish Journal of Pharmacology, 2013
- A G Protein-Biased Ligand at the μ-Opioid Receptor Is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with MorphineThe Journal of Pharmacology and Experimental Therapeutics, 2013
- A Simple Method for Quantifying Functional Selectivity and Agonist BiasACS Chemical Neuroscience, 2012
- Quantifying Ligand Bias at Seven-Transmembrane ReceptorsMolecular Pharmacology, 2011
- Therapeutic potential of β-arrestin- and G protein-biased agonistsTrends in Molecular Medicine, 2011
- Hill coefficients, dose–response curves and allosteric mechanismsJournal of Chemical Biology, 2009
- JNJ-20788560 [9-(8-Azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3-carboxylic Acid Diethylamide], a Selective Delta Opioid Receptor Agonist, Is a Potent and Efficacious Antihyperalgesic Agent That Does Not Produce Respiratory Depression, Pharmacologic Tolerance, or Physical DependenceThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Characterizing Cannabinoid CB2 Receptor Ligands Using DiscoveRx PathHunter™ β-Arrestin AssaySLAS Discovery, 2009
- Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the µ-opioid-receptor geneNature, 1996